Business Context and Reporting Period
This Form 8-K Current Report was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on August 16, 2022. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The report details a new borrowing event and the issuance of unregistered equity securities.
Key Financial Metrics and Obligations
- New Borrowing: AgeX borrowed an additional $1,000,000 under a Secured Convertible Promissory Note with Juvenescence Limited.
- Total Outstanding Principal: The cumulative amount borrowed under the line of credit is now $11,160,000.
- Remaining Credit Availability: $2,000,000 remains available for future draws, subject to lender discretion and a $1,000,000 cap per single draw.
- Repayment Date: The outstanding principal balance is due on February 14, 2024.
- Cost of Capital: Instead of accrued interest, the company pays an Origination Fee of 4% on each draw and an additional 4% on the total drawn amount after the 12-month draw period.
- Equity Issuance: In connection with the draw, AgeX issued warrants to purchase 746,380 shares of common stock at an exercise price of $0.6699 per share.
Material Changes Versus Prior Period
The filing reports a material increase in debt obligations and equity dilution potential compared to the prior period. The total principal balance under the Secured Note increased from $10,160,000 to $11,160,000 following the August 16 draw. Additionally, the company has incurred new warrant obligations not present in the prior reporting cycle.
Guidance, Risks, and Contingencies
- Events of Default: The note contains extensive default provisions, including failure to pay principal or fees, breach of covenants, cross-defaults on other indebtedness exceeding $100,000, insolvency, bankruptcy proceedings, and material asset dispositions exceeding $250,000.
- Acceleration: Upon an Event of Default, the entire outstanding principal and accrued fees may become immediately due and payable.
- Forward-Looking Statements: The company disclaims any obligation to update forward-looking statements and warns that actual results may differ materially from anticipated results due to various risk factors.
- Liquidity Constraints: Future draws are subject to the lender's discretion, and the company is restricted to a maximum of $1 million per subsequent draw.
Investor Verification Checklist
- Verify the total outstanding debt load of $11.16 million against the company's current cash position and liquidity runway.
- Confirm the dilution impact of the 746,380 warrants issued at $0.6699 per share.
- Review the company's ability to meet the February 14, 2024, repayment deadline or refinance the obligation.
- Assess the risk of cross-default triggers related to other indebtedness exceeding $100,000.
- Check for any subsequent filings regarding the remaining $2 million credit line availability.